On the other side, SGLT2 inhibitor administration shorter than one year correlated to significantly lower EC incidence than non-SGLT2 inhibitors in T2DM population (aHR: 0.58, 95% CI: 0.45-0.73) (Table 3). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.